Trial Profile

A Phase III Study of JR-141 in Patients With Mucopolysaccharidosis II (STARLIGHT

Status: Recruiting

Phase of Trial: Phase III

Latest Information Update: 03 Feb 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Pabinafusp alfa (Primary) ; Pabinafusp alfa (Primary) ; Idursulfase
Indications Mucopolysaccharidosis II
Focus Registrational; Therapeutic Use
Acronyms Starlight
Sponsors JCR Pharmaceuticals

Most Recent Events

14 Feb 2024 According to a JCR Pharmaceuticals, updated study design of this trial presented at the 20th Annual WORLDSymposium, 2024.
13 Nov 2023 According to a JCR Pharmaceuticals, the company have 17 sites in the US, Europe, and Brazil active, and we are trying to activate more sites to further enhance and accelerate enrollment. In Q1 2024, the company expect to have all patients involved that are necessary for the interim analysis.
12 Jun 2023 Planned End Date changed from 31 Oct 2026 to 31 Jan 2026.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com